摘要
目的：观察细胞因子诱导的杀伤细胞（CIK）和树突状细胞（DC）联合白细胞介素－2（IL－2）治疗肺部转移晚期肾癌患者根治性肾切除术后的临床疗效。方法66例肺部转移的肾癌患者在行根治性肾切除术后随机分为3组：IL－2联合CIK－DC组（ IL－2＋CIK组）22例、IL－2组22例、CIK－DC组22例。观察3组患者临床疗效、生活质量、免疫指标的变化。结果 IL－2＋CIK组总有效率（ CR＋PR）为81．8％，明显高于IL－2组（50．0％）、CIK－DC组（45．5％）（P均＜0．05）；IL－2＋CIK组、IL－2组、CIK－DC组Kamofsky评分总提高率分别为95．5％、68．2％、72．7％，IL－2＋CIK组总提高率明显高于IL－2组、CIK－DC组（P＜0．05）；IL－2＋CIK组患者的CD3＋、CD4＋、CD4／CD8比值均较治疗之前有明显升高（ P＜0．05）。结论 IL－2联合CIK－DC对行根治性肾切除术后中晚期肾癌患者的近期疗效较好，可显著改善患者的生活质量以及免疫功能。
Objective To observe the effects of cytokine induced killer （ CIK） cells and dendritic cells （ DCs） in combination with IL-2 in the treatment of renal cell carcinoma metastatic to the lungs after radical nephrectomy.Meth-ods A total of 66 patients with renal cell carcinoma metastatic to the lungs were randomly divided into three groups after radical nephrectomy （n=22）：a study group treated with IL-2 combined with CIK-DCs, a control group A administra-ted with IL-2, and a control group B given CIK-DCs.Then, changes in clinical efficacy, quality of life and immuno-logical index of each group were observed.Results After treatment, the total effective rate （CR＋PR） was 81.8%for the study group, which was remarkably higher than 50%for the control group A and 45.5%for the control group B （P〈0.05）.The Kamofsky score was increased by 95.5%for the study group, which was markedly higher than 68.2%for the control group A and 72.7%for the control group B （P〈0.05）.After treatment, patients in the study group pro-duced substantially enhanced levels of CD3^＋ and CD4^＋, and CD4/CD8 ratio than their pre -treatment levels （ P〈0.05）.Conclusion IL-2 can be used in combination with CIK-DCs to treat renal cell carcinoma patients at medium and advanced phases after radical nephrectomy, producing good short-term efficacy and significant improvement in qual-ity of life and immunological function.
出处
《徐州医学院学报》
CAS
2015年第12期917-920,共4页
Acta Academiae Medicinae Xuzhou
基金
徐州市科技计划项目（KC14SH099）
